{"id":"W4415315812","doi":"10.1016/j.jiac.2025.102834","title":"Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study","year":2025,"lang":"en","type":"article","venue":"Journal of Infection and Chemotherapy","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Janssen Pharmaceuticals; ViiV Healthcare","keywords":"Rilpivirine; Tenofovir alafenamide; Adverse effect; Regimen; Randomized controlled trial; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003072477,0.00116358,0.00209508,0.0003472043,0.0004036758,0.001189248,0.0007288018,0.001599288,0.00518943],"category_scores_gemma":[0.00270738,0.0004773017,0.003270309,0.0003190539,0.000848076,0.0011736,0.0004399628,0.002883219,0.0007230407],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006271373,"about_ca_system_score_gemma":0.0008147159,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008647404,"about_ca_topic_score_gemma":0.001696863,"domain_scores_codex":[0.9985321,0.0008023241,0.0001041949,0.0002008889,0.0001255538,0.000235041],"domain_scores_gemma":[0.9973297,0.0007618969,0.0007085293,0.0002187753,0.0002131188,0.0007679938],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9746398,0.006648735,0.006191378,0.000200711,0.001485976,0.00002816051,0.00004540849,0.0003274151,0.0008538011,0.0000462271,0.0006071946,0.008925119],"study_design_scores_gemma":[0.5440511,0.387992,0.05884944,0.0001073672,0.004053019,0.00009348042,0.0001374448,0.001660249,0.001350463,0.0004959117,0.00114683,0.00006270606],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996323,0.001161064,0.0001397285,0.0001452841,0.0001114506,0.0003836172,0.0008002964,0.00002335832,0.0009122575],"genre_scores_gemma":[0.9966347,0.0004278652,0.0002365749,0.0003060195,0.0001462087,0.0004222196,0.000922149,0.000008184931,0.0008960468],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00518943,"threshold_uncertainty_score":0.01736033,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01484259345914538,"score_gpt":0.334879915434438,"score_spread":0.3200373219752926,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}